NOV 02, 2016
In this interview from AAO 2016, Dr. William R. Freeman discusses a phase 2 trial evaluating use of the glaucoma drug brimonidine for geographic atrophy (GA). Dr. Freeman’s team injected a long-acting formulation of brimonidine into the vitreous cavity of patients with GA. The initial results showed significant slowing of disease progression with no adverse effects, representing an exciting potential breakthrough in treating this currently incurable disease. Allergan has completed enrollment of a follow-up study aiming to develop a more potent delivery method.